Search results for "hyperplasia"

showing 10 items of 251 documents

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

2013

To present a summary of the 2013 version of the European Association of Urology guidelines on the treatment and follow-up of male lower urinary tract symptoms (LUTS). We conducted a literature search in computer databases for relevant articles published between 1966 and 31 October 2012. The Oxford classification system (2001) was used to determine the level of evidence for each article and to assign the grade of recommendation for each treatment modality. Men with mild symptoms are suitable for watchful waiting. All men with bothersome LUTS should be offered lifestyle advice prior to or concurrent with any treatment. Men with bothersome moderate-to-severe LUTS quickly benefit from α1-blocke…

Malemedicine.medical_specialtyPhosphodiesterase Inhibitorsmedicine.medical_treatmentUrologyUrologyProstatic HyperplasiaMuscarinic AntagonistsSeverity of Illness Indexchemistry.chemical_compound5-alpha Reductase InhibitorsLower Urinary Tract SymptomsLower urinary tract symptomsmedicineNocturiaHumansWatchful WaitingTransurethral resection of the prostateUrinary retentionProstatectomybusiness.industryTransurethral Resection of Prostatemedicine.diseaseDutasterideTreatment OutcomechemistryAdrenergic alpha-1 Receptor AntagonistsUrological AgentsProstate surgeryStentsmedicine.symptombusinessUrinary CatheterizationRisk Reduction BehaviorWatchful waitingEuropean urology
researchProduct

Benign focal liver lesions: spectrum of findings on SonoVue-enhanced pulse-inversion ultrasonography.

2005

The prevalence of benign focal liver lesions (BFLL) is high both in the general population and in patients with known malignancies. The gray-scale ultrasound (US) technique is usually the first-line imaging modality used in the radiological workup of such lesions, but unfortunately it lacks specificity. Furthermore, Doppler examination may often be unsatisfactory owing to motion artefacts, or when small or deeply located lesions are evaluated. Recently, microbubble-based contrast agents used in combination with gray-scale US techniques, which are very sensitive to nonlinear behavior of microbubbles, have led to a better depiction of both microvasculature and macrovasculature of focal hepati…

Malemedicine.medical_specialtyPopulationSulfur HexafluorideContrast MediaAdenoma Liver CellmedicineHumansRadiology Nuclear Medicine and imagingIn patienteducationPhospholipidsNeuroradiologyUltrasonographyeducation.field_of_studymedicine.diagnostic_testbusiness.industryLiver DiseasesUltrasoundLiver NeoplasmsInterventional radiologyGeneral MedicinePulse inversionFocal Nodular HyperplasiaMicrobubblesFemaleRadiologyUltrasonographybusinessHemangioma
researchProduct

Outcome of radical prostatectomy for incidental carcinoma of the prostate

2009

OBJECTIVE To evaluate a contemporary series of patients with incidental prostate cancer detected by transurethral resection of the prostate (TURP) and undergoing radical prostatectomy (RP). PATIENTS AND METHODS Between 1998 and 2004, 1931 patients had TURP for obstructive voiding symptoms and suspected BPH. Incidental prostate cancer was found in 104 (5.4%); 26 of these patients had a RP. The pathological staging and treatment of these patients were reviewed retrospectively and the follow-up results obtained. RESULTS Of the 26 patients who had RP, 17 had T1a and nine had T1b carcinoma of the prostate. After RP, six (35%) in the T1a group had no residual tumour (pT0) and 11 (65%) had pT2 can…

Malemedicine.medical_specialtyProstate biopsyUrologymedicine.medical_treatmentPathological stagingProstatic HyperplasiaUrologyurologic and male genital diseasesProstate cancerProstatemedicineHumansAgedTransurethral resection of the prostateProstatectomyIncidental Findingsmedicine.diagnostic_testbusiness.industryProstatectomyProstatic NeoplasmsCancerMiddle AgedProstate-Specific Antigenmedicine.diseaseTreatment Outcomemedicine.anatomical_structureHormonal therapyEpidemiologic MethodsbusinessProstatismBJU International
researchProduct

Androgen receptor assays in specimens of prostatic tissue obtained by transurethral resection and transvesical adenomectomy

1991

The main goal of this study was to ascertain whether routine transurethral resection (TUR) of prostate may provide useful material for the evaluation of androgen receptor (AR) status. At the same time, either intracellular distribution of binding affinity and capacity of receptor molecules were particularly taken into account. Based on our previous findings in breast and endometrial cancer, we suggest that a "functional" receptor status may correspond to the presence of type I (high affinity, low capacity) AR in both soluble and nuclear fractions. However, the precise significance of type II (lower affinity, higher capacity) binding sites remains to be clarified. Ten samples of large prosta…

Malemedicine.medical_specialtyReceptor StatusUrologymedicine.medical_treatmentProstatic HyperplasiaUrologySpecimen HandlingRadioligand AssayProstateInternal medicineElectrocoagulationmedicineRadioligandHumansMiboleroneReceptorProstatectomyChemistryEndometrial cancerProstatemedicine.diseaseIn vitroAndrogen receptorEndocrinologymedicine.anatomical_structureReceptors AndrogenUrological Research
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct

Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia.

2002

<i>Introduction:</i> The aim of our study is to verify the effects of doxazosin on sexual function in patients with benign prostatic hyperplasia (BPH). <i>Materials and Methods:</i> We enrolled 102 patients with BPH, selected by nine Italian Urology Departments. Patients were evaluated with the International Prostatic Symptom Score (I-PSS) and divided into two groups: those with intact sexual activity and those with erectile dysfunction. According to the International Index of Erectile Function (IIEF), the second cohort was divided into three subgroups on the basis of the degree of erectile dysfunction degree (severe, moderate or mild). All patients underwent 3 month…

Malemedicine.medical_specialtyTime FactorsAdenomaUrologyUrologyProstatic Hyperplasiaurologic and male genital diseasesProstatemedicineDoxazosinHumansAdrenergic alpha-AntagonistsGynecologyurogenital systembusiness.industryPenile ErectionDoxazosinHyperplasiamedicine.diseasemedicine.anatomical_structureErectile dysfunctionCase-Control StudiesObservational studySexual functionbusinessmedicine.drugCohort studyFollow-Up Studies
researchProduct

Optical Coherence Tomography Versus Intravascular Ultrasound to Evaluate Coronary Artery Disease and Percutaneous Coronary Intervention

2013

ObjectivesWe compared intravascular ultrasound (IVUS) and 2 different generations of optical coherence tomography (OCT)—time-domain OCT (TD-OCT) and frequency-domain OCT (FD-OCT)—for the assessment of coronary disease and percutaneous coronary intervention (PCI) using stents.BackgroundOCT is a promising light-based intravascular imaging modality with higher resolution than IVUS. However, the paucity of data on OCT image quantification has limited its application in clinical practice.MethodsA total of 227 matched OCT and IVUS pull backs were studied. One hundred FD-OCT and IVUS pull backs in nonstented (n = 56) and stented (n = 44) vessels were compared. Additionally, 127 matched TD-OCT and …

Malemedicine.medical_specialtyTime Factorsgenetic structuresmedicine.medical_treatmentTreatment outcomeSeverity of Illness Indexintravascular ultrasoundCoronary RestenosisCoronary artery diseaseOptical coherence tomographyPredictive Value of TestsNeointimaIntravascular ultrasoundmedicineHumanscardiovascular diseasesUltrasonography InterventionalAgedCell ProliferationAnalysis of VarianceHyperplasiaoptical coherence tomographymedicine.diagnostic_testbusiness.industrypercutaneous coronary interventionCoronary StenosisPercutaneous coronary interventionMiddle Agedequipment and suppliesmedicine.diseaseCoronary Vesselseye diseasesTreatment Outcomesurgical procedures operativeLinear ModelsFemaleStentssense organsTomographyRadiologyUltrasonographybusinessCardiology and Cardiovascular MedicineTomography Optical CoherenceJACC: Cardiovascular Interventions
researchProduct

Testosterone metabolism in benign prostatic hypertrophy: in vivo studies of gestonorone caproate and cyproterone acetate.

1976

Summary 18 patients with obstructive benign prostatic hypertrophy were studied. A 5-day treatment with gestonorone caproate (200 mg daily and 200 mg on alternate days) and cyproterone acetate (300 mg daily) suppressed the plasma LH and serum LH levels. Subsequently, H3-testosterone was injected intravenously and its elimination from plasma and uptake and metabolism in the BPH tissue studied. The elimination of total radioactivity and H3-testosterone from plasma was not altered after the 3 treatment regimens as compared to the control group. The uptake of total radioactivity into BPH tissue and its intraprostatic metabolism particularly to dihydrotestosterone was significantly suppressed in …

Malemedicine.medical_specialtyUrologyProstatic HyperplasiaMuscle hypertrophychemistry.chemical_compoundIn vivoInternal medicinemedicineHumansTestosteroneCyproteroneTestosteroneGestonorone caproateAgedClinical Trials as TopicTreatment regimenbusiness.industryProstateCyproterone acetateMetabolismLuteinizing HormoneMiddle AgedEndocrinologychemistryDihydrotestosteronebusinessGestonorone Caproatemedicine.drugBritish journal of urology
researchProduct

Persistent storage symptoms after TURP can be predicted with a nomogram derived from the ice water test

2019

PURPOSE To predict the persistence of storage symptoms after transurethral resection of the prostate (TURP) using a nomogram derived from the ice water test (IWT). METHODS The IWTs of 73 men with lower urinary tract symptoms and prostatic bladder outlet obstruction were retrospectively analyzed. The strength of the detrusor contraction was approximated by using the detrusor gradient of Δpdet /Δt at maximum detrusor pressure and the area under the curve. The parameters were utilized in a nomogram, which facilitated a severity categorization from 1 to 10. Patients with a positive IWT in the categories 1 to 2 were assigned to group A, categories 3 to 4 to group B and categories 5 and higher to…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentProstatic Hyperplasia030232 urology & nephrologyUrologyurologic and male genital diseasesGroup BPersistence (computer science)03 medical and health sciencesBladder outlet obstruction0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineHumansAgedRetrospective StudiesTransurethral resection of the prostateAged 80 and over030219 obstetrics & reproductive medicineUrinary Bladder Overactivebusiness.industryTransurethral Resection of ProstateArea under the curveDiagnostic Techniques UrologicalMiddle AgedNomogrammedicine.diseaseBotulinum toxinUrinary Bladder Neck ObstructionNomogramsUrodynamicsNeurology (clinical)businessmedicine.drugNeurourology and Urodynamics
researchProduct

Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.

2007

Drug-eluting stents are increasingly used to reduce in-stent restenosis and adverse cardiac events after percutaneous coronary interventions. However, the race for the ideal drug-eluting stent is still on, with special regard to the best stent-coating system and the most effective and less toxic drug. Fludarabine, a nucleoside analog, has both anti-inflammatory and antiproliferative cellular effects. The aim of the present study was to assess the cellular and molecular effects of fludarabine on vascular smooth muscle cell (VSMC) growth in vitro and in vivo and the feasibility and efficacy of a fludarabine-eluting stent. To study the biomolecular effects of fludarabine on VSMC proliferation…

Malemedicine.medical_specialtyVascular smooth muscleTime FactorsPhysiologyMyocytes Smooth MusclePharmacologyProsthesis DesignTransfectionMuscle Smooth VascularRestenosisIn vivoPhysiology (medical)medicineAnimalsCarotid StenosisRNA AntisensePhosphorylationRats WistarAortaCells CulturedCell ProliferationNeointimal hyperplasiaHyperplasiaDose-Response Relationship Drugbusiness.industryCardiovascular AgentsHyperplasiaJanus Kinase 2medicine.diseaseFludarabineSurgeryRatsDisease Models AnimalSTAT1 Transcription FactorCardiovascular agentSTAT proteinFeasibility StudiesStentsRabbitsCardiology and Cardiovascular MedicinebusinessCarotid Artery InjuriesTunica IntimaAngioplasty BalloonVidarabinemedicine.drug
researchProduct